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Abstract  
Neurodegenerative diseases ranging from Alzheimer’s disease and polyglutamine 
diseases to transmissible spongiform encephalopathies are associated with the 
aggregation and accumulation of misfolded proteins. In several cases the intracellular and 
extracellular protein deposits contain a fibrillar protein species called amyloid. However 
while amyloid deposits are hallmarks of numerous neurodegenerative diseases, their 
actual role in disease progression remains unclear. Especially perplexing is the often poor 
correlation between protein deposits and other markers of neurodegeneration. As a result 
the question remains whether amyloid deposits are the disease causing species, the 
consequence of cellular disease pathology or even the result of a protective cellular 
response to misfolded protein species. Here we highlight studies that suggest that 
accumulation and sequestration of misfolded protein in amyloid inclusion bodies and 
plaques can serve a protective function. Furthermore, we discuss how exceeding the 
cellular capacity for protective deposition of misfolded proteins may contribute to the 
formation of toxic protein species.  
 
Introduction 
The study of neurodegenerative diseases began over a hundred years ago when 
Alois Alzheimer identified fibrillar structures within the postmortem brain of a patient 
who had exhibited progressive cognitive dysfunction and psychosis1. It is now known 
that the majority of neurodegenerative diseases characterized by progressive neuronal 
dysfunction and loss are associated with the deposition of misfolded proteins. These 
misfolded proteins are frequently found in a β-sheet rich fibrillar protein conformation 
known as amyloid2, 3 (Figure 1). For more than forty years amyloid deposits were thought 
to be causative agents in the degenerative process4. But the tables have turned. Recent 
studies suggest instead that a group of still poorly defined pre-amyloid species, rather 
than the amyloid deposits themselves, are the true toxic conformations 5-8 (Figure 1). 
These soluble prefibrillar oligomers share conformational characteristics independent of 
the proteins primary amino acid sequences and may share a common mechanism of 
toxicity5. Indeed even proteins completely unrelated to disease, such as PI3 kinase and 
the E. Coli protein HypF-N, can be induced to form such prefibrillar structures in vitro 
and, when they do, they are toxic when applied extracellularly to cells in culture or 
injected into rat brains9, 10. The intra- and extracellular conversion of misfolded proteins 
into highly structured and less reactive amyloid forms may reduce the levels of these 
toxic protein species and therefore be protective.  
For the purpose of this perspective, we focus on three neurodegenerative diseases, 
Alzheimer’s, Huntington’s and prion disease. We will first present studies in which the 
formation of inclusion bodies and amyloid plaques protects against proteotoxicity and 
then discuss how exceeding the cellular capacity for deposition of misfolded proteins 
may give rise to toxic protein species. Although these studies do not preclude detrimental 
effects of amyloid deposits in particular contexts (eg. obstructive vascular amyloid), they 
clearly show that amyloid formation can be beneficial. 
  
Pathological features associated with neurodegenerative diseases 
The protein deposits found in Alzheimer’s, Huntington’s and prion disease are 
formed by completely unrelated proteins. They accumulate in distinct brain regions and 
have highly characteristic morphologies that form the basis of histological diagnosis.  
Neurodegeneration also affects distinct regions of the brain in each diseases, reflecting 
disease specific vulnerability of particular neurons11. However, in all three diseases the 
correlation between the localization of neurodegeneration and protein deposition is weak. 
Alzheimer’s disease (AD), the most common cause of dementia, most severely 
affects the temporal pole, hippocampus and amygdala12. AD is characterized by the 
accumulation of two very different proteins, each with a distinct distribution. Aβ 
(amyloid β)  peptide accumulates extracellularly in amyloid plaques while 
hyperphosphorylated tau, a microtubule binding protein, accumulates intracellularly in 
neurofibrillary tangles. A definitive pathological diagnosis of AD requires the detection 
of both types of aggregation. Aβ may accumulate in different plaque forms. Neuritic 
plaques, also referred to as classic or cored plaques, contain a dense amyloid core 
surrounded in turn by a ring of abnormal cellular processes and a rim of diffuse 
amyloid11, 12. In these neuritic plaques tau accumulation can also be present in dystrophic 
neurites surrounding the amyloid core.  
It has been hypothesized that Aβ accumulation is the primary cause of 
pathogenesis in AD, yet there is a weak correlation between Aβ plaque density and the 
severity of dementia11. For example, brain samples of aged patients without clinical 
dementia can display abundant Aβ plaques11. To some extent this may be the 
consequence of Aβ accumulating in plaques without any associated neuritic degeneration 
(such as “burned-out” and “diffuse plaques”). Tau-containing neurofibrillary tangles 
correlate better with clinical severity of AD than Aβ plaques, but even here, the question 
remains whether tau aggregation itself is toxic or if it is the result of a protective 
mechanism 13-16.  
Huntington’s disease (HD), classified as a hyperkinetic movement disorder, 
tends to affect brain regions distinct from those affected by Alzheimer’s disease. HD is 
characterized by atrophy of the cerebral cortex, globus pallidus and striatum, specifically 
with loss of medium spiny neurons within the neostriatum17-19. HD is caused by CAG 
repeat expansions in the huntingtin gene, which lead to the accumulation of 
polyglutamine-expanded Huntingtin protein within intranuclear inclusion bodies or 
neurites11. The density of intranuclear inclusions correlates positively with the CAG 
repeat length present in the huntingtin gene20. However neuronal vulnerability does not 
correspond to the cellular concentration of Huntingtin protein nor the distribution of 
Huntingtin inclusions21. In fact there is a distinct dissociation of inclusion distribution 
and the selective pattern of striatal neuron loss, as few to no inclusions are detected in the 
vulnerable striatal neurons22. 
Prion diseases or spongiform encephalopathies can present in numerous ways, 
such as sporadic versus variant Creutzfeldt-Jakob disease (CJD). While the prion disease 
subtypes all involve the accumulation of a proteinase-K resistant form of the prion 
protein PrP (PrPres), they each affect different brain regions and involve distinct patterns 
of PrP aggregation11. Sporadic CJD causes spongiform change in the neuropil of the 
cerebral cortex, subcortical grey matter and cerebellar molecular layer23. The brainstem 
and spinal cord do not exhibit spongiform change although PrP deposits can be present. 
PrPres deposits in sporadic CJD are found in synaptic, perivacuolar, perineuronal and 
plaque-like patterns23. However neuronal loss correlates with microglial activation and 
axonal damage, but not with local deposition of PrPres. In contrast, variant CJD, caused 
by the consumption of meat from cows with Bovine Spongiform Encephalopathy, leads 
to the presence of a large number of florid plaques in the cerbral and cerebellar cortex24. 
Florid plaques have a dense amyloid core, a pale radiating fibrillar periphery and are 
surrounded by a halo of spongiform change. Interestingly, spongiform change in variant 
CJD is most pronounced in the basal ganglia, which contain relatively few amyloid 
plaques24.  
 In summary, while the particular misfolded proteins vary in these diseases, in all 
three cases protein deposits are a poor indicator of neuronal loss. This makes it plausible 
that structured protein deposits help cells cope with misfolded proteins. In turn, the 
failure of particular neurons to create such deposits may cause their disease specific 
vulnerability.  
 
Protein deposition as a cellular response to misfolded proteins 
One of the first indications that protein inclusions may protect cells from toxic 
misfolded proteins came from a study investigating the response of tissue culture cells to 
either proteasome inhibitors or to overexpression of proteins targeted to the proteasome. 
The Kopito laboratory established that exceeding the proteasome’s capacity to cope with 
misfolded proteins, by either perturbation, leads to the accumulation of stable aggregates 
at a distinct structure adjacent to the centrosome25. This structure was termed the 
aggresome to emphasize that its formation is a common cellular response to the presence 
of aggregated misfolded protein.  
The aggresome is highly structured deposit of insoluble protein surrounded by a 
cage formed by the intermediate filament protein vimentin. Most strikingly, aggresomes 
are actively formed near the centrosome through dynein-dependent retrograde transport 
of protein aggregates along microtubules25-27. Far from being amorphous protein 
accumulations, aggresomes are formed through an active and conserved cellular process, 
that appears to serve a vital purpose: sweeping the cytoplasm clear of potentially toxic 
aggregates of misfolded proteins28.  
 
Protein deposition as a protective mechanism 
A host of studies involving proteins linked to neurodegenerative diseases and 
other amyloidogenic proteins have investigated the role of inclusion and plaque 
formation in pathogenicity. The case is perhaps strongest for Huntington’s disease, for 
which it has been postulated that inclusions cause toxicity due to the sequestration of 
proteins critical for cell homeostasis29. Indeed, inclusions formed by mutant Huntingtin 
protein have been shown to sequester glyceraldehydes-3-phosphate dehydrogenase, to 
impair transcription due to sequestration of the transcriptional coactivator CREB binding 
protein, and to interfere with the function of the ubiquitin-proteasome system30-32. 
However smaller oligomeric species and loosely packed amorphous aggregates may be 
more prone to interact with and sequester proteins than densely packed amyloid deposits.  
Indeed, several studies suggest that the formation of tightly packed Huntingtin 
deposits is beneficial for cell survival. The Greenberg lab demonstrated that transfection 
of mutant huntingtin into primary striatal neurons induced the formation of inclusions33. 
The inclusions formed resembled protein deposits found in the brains of Huntington 
patients, as they were intranuclear and ubiquitinylated. But inclusions were not sufficient 
to induce apoptosis. On the contrary, inhibiting the ubiquitinylation of mutant Huntingtin 
prevented the formation of inclusions and actually increased cell death33.  
In a complementary study, the Finkbeiner group used time-lapse microscopy to 
follow the fate of individual huntingtin transfected neurons. The majority of neurons died 
without the formation of inclusion bodies and the formation of an inclusion body actually 
increased the probability of neuron survival34. The formation of inclusion bodies directly 
correlated with a decrease in soluble Huntingtin, suggesting that inclusion bodies protect 
neurons by decreasing levels of soluble toxic isoforms of Huntingtin34. Inclusion body 
formation could also serve a protective function by increasing the autophagic degradation 
of the aggregated protein species35. Inclusions of mutant Huntingtin directly induce 
autophagy through sequestration of mTOR, a negative regulator of autophagy, and 
autophagy not only reduces the levels of aggregated but also soluble mutant huntingtin36, 
37.  
Together, these studies suggest that compounds elevating the formation of 
inclusion bodies, such as aggresomes, could lessen cellular pathology. On the other hand 
compounds antagonizing the toxicity of mutant huntingtin by reducing its aggregation 
have been identified38. On the surface, this appears to conflict with the notion that 
promoting inclusions may be beneficial, but both, solubilization and inclusion body 
formation, may diminish the levels of toxic oligomers, the more critical species in 
pathogenesis. In fact, in a HD model a compound could prevent huntingtin-mediated 
proteasome dysfunction by promoting inclusion formation39. 
Although the characteristic protein deposits are found extracellularly in AD and 
prion disease, not intracellularly as in HD, here too studies suggest that structured protein 
deposits are less toxic than other conformers. As for HD, amyloid assembly may serve a 
beneficial function by shifting the equilibrium away from more toxic conformers, such as 
prefibrillar oligomers5, 6, 8.  
 In a collaborative effort, the Kelly and Dillin laboratories investigated the roles of 
the aging process and the heat shock response in the formation of proteotoxic species in a 
Caenorhabiditis elegans model of AD. The intracellular expression of Aβ resulted in the 
formation of Aβ aggregates, but these aggregates did not correlate with toxicity40. RNAi 
mediated repression of the insulin/IGF-1 receptor DAF-2, resulting in increased life span, 
reduced Aβ-mediated toxicity while slightly increasing the amount of Aβ aggregates. 
This protection depended on both daf-16 and hsf-1. Interestingly, repression of DAF-16 
reduced the number of high molecular weight Aβ aggregates, while repression of HSF-1 
increased it. The Kelly and Dillin laboratories concluded that two dichotomous cellular 
pathways counteract Aβ toxicity: The HSF-1 pathway controls disaggregation, while the 
DAF-16 pathway transforms toxic Aβ oligomers into larger Aβ aggregates of lower 
toxicity40. 
In a separate study by the Mucke group, a point mutation within Aβ, the Arctic 
mutation (Aβ E22G), influenced the rate at which Aβ assembled into amyloid fibers. In 
vitro and in transgenic mice, the Artic mutation enhanced formation of neuritic amyloid 
plaques and diminished non-amyloid Aβ assemblies41. As non-amyloid Aβ assemblies 
correlated with behavioral and neuronal deficits in these transgenic mice, the promotion 
of Aβ amyloid fibril formation, without a coinciding increase in oligomeric Aβ, may be 
beneficial. 
Most recently, in a follow-up study of a clinical trial, the immunization of AD 
patients with the full length Aβ peptide exhibited reduced Aβ immunostaining and 
amyloid plaques42. Unfortunately, immunization neither slowed nor stopped the 
progression of neurodegeneration. As immunization with Aβ peptide may not have 
reduced the levels of toxic oligomeric Aβ species, the authors suggest, that immunization 
specifically against oligomeric Aβ species may be more successful at halting 
neurodegeneration.  
Plaque formation may also prove beneficial in the case of prion disease. PrPres 
isoforms, the protease resistant forms of PrP that include amyloid, are not toxic on their 
own. Mice that do not express their own PrP protein (Prn-p0/0) are completely resistant to 
the intracerebral injection of even very high doses PrPres43. Equally striking, mice 
producing a secreted form of PrP, GPI anchor-less PrP, accumulated massive plaque-like 
amyloid deposits, yet had no clinical manifestations of prion disease44. Some brain 
lesions were present, but there was less neurodegeneration associated with these amyloid 
plaques than with diffuse wild type PrPres deposits. These results were especially 
significant as transgenic mice had up to 40% more PrPres in comparison to mice with 
WT PrP44. Using human tissue samples, the Barron laboratory showed that the 
accumulation of certain forms of PrPres failed to result in spongiform degeneration. 
Brain extracts from two cases of familial prion disease were used to test the transmission 
of disease to transgenic mice. One of the samples exhibited PrPres deposits and 
spongiform change, while the other presented with PrPres deposits and no spongiform 
change. Brain extract from the patient without spongiform degeneration did not result in 
disease transmission but elicited PrPres deposition in large multicentric plaques. 
Therefore, PrPres would appear to be rendered nonpathogenic by its sequestration in 
amyloid plaques45. 
 
Lessons from a yeast model 
 Yeast prion proteins, just as PrP, can adopt self-perpetuating conformational 
states. In yeast, however, prions do not cause disease, but rather serve as heritable genetic 
elements, perpetuated by the transfer of the prion template from mother to daughter 
cells46. The heritable protein conformation of the yeast prions is amyloid in nature and, as 
for Aβ, Huntingtin and PrP, amyloid formation by the yeast prion proteins proceeds 
through intermediate oligomeric protein species47, 48.  In fact, the observation that 
prefibrillar oligomers are intermediates in amyloid formation was first made for the yeast 
prion protein Sup3547, 49. Oligomers formed by the yeast prion protein Sup35 share 
structural features with the oligomers formed by disease-related amyloidogenic proteins, 
these include recognition by anti-oligomeric antibodies and interaction with specific 
small compounds49, 50. Thus the study of yeast prions can provide insight into amyloid 
formation and cellular responses to the presence of amyloid.  
The yeast prion [RNQ+] is formed by the Rnq1 protein (The cytoplasmic 
inheritance of yeast prions is designated by [ ]). Rnq is nonessential and has no known 
biological function, except when it is in prion state51. In this case the [RNQ+] prion 
interacts with other amyloidogenic proteins in vivo and enables them to adopt their 
amyloid conformation. For example, [RNQ+] facilitates the de novo induction of the 
[PSI+] prion state by enhancing the amyloid conversion of the yeast prion protein 
Sup3552.  
We recently reported that moderate ectopic overexpression of Rnq1 is extremely 
toxic if endogenous Rnq1 is in the [RNQ+] prion conformation53. While overexpression 
of Rnq1 did result in the formation of amyloid inclusions, as assessed by Thioflavin-T 
staining, semi-denaturing agarose gels and in vitro seeding assays, the amyloid 
conformation did not represent the toxic species. In fact, co-expression of an Hsp40 
chaperone, Sis1, known to interact with the prion form of Rnq154, suppressed the toxicity 
elicited by Rnq1 overexpression by promoting Rnq1 assembly into amyloid. Mutants of 
Rnq1, impaired in their interaction with the chaperone and their ability to readily form 
amyloid, exhibited enhanced toxicity. Chaperones have been shown to antagonize 
toxicity associated with protein misfolding before, but in those cases overexpressed 
chaperones either decreased protein aggregation55 or appeared to have no observable 
effect on protein aggregation56. This study presents the first instance in which a 
chaperone antagonizes the toxicity of a misfolding protein by facilitating its deposition 
into an amyloid inclusion. It clearly demonstrates that actively promoting the formation 
of inclusion bodies and even amyloid plaques may prove beneficial in protein misfolding 
pathologies.  
  
Formation of toxic protein species due to non-productive templating 
While the formation of aggresomes and extracellular amyloid plaques appears to 
serve a protective function, they could be associated with toxicity if their assembly is 
overwhelmed by the amount of protein damage or impeded by other molecular and 
cellular factors. As shown by the Kampinga group, aggresome formation by mutant 
huntingtin in tissue culture cells did not affect the cellular progression through mitosis. 
However, when the mutant huntingtin formed scattered secondary inclusions, the 
completion of mitosis was delayed or even failed completely57. The Kampinga group 
speculated that these secondary inclusions, distinct from aggresomes, form when the 
process of aggresome formation is saturated57.  These results are reminiscent of our 
studies in which overexpression of the yeast prion protein Rnq1 resulted in toxicity when 
it exceeded the cellular capacity to efficiently assemble the prion protein into amyloid. 
The toxicity of Rnq1 overexpression was exacerbated by factors interfering with amyloid 
assembly, such as repression of Sis1, the chaperone required for Rnq1 amyloid 
formation, or mutations within Rnq1, which reduce its interaction with the chaperone53.  
Importantly, Rnq1 overexpression only resulted in toxicity if the endogenous 
Rnq1 protein was in its [RNQ+] prion conformation, making the otherwise benign prion 
state a prerequisite for Rnq1 mediated toxicity. Interestingly, the Rnq1 prion state is also 
required for toxicity of mutant huntingtin exon 1 in yeast models of Huntington’s 
disease58. While the Rnq1 prion conformation usually acts as a template for the 
conversion of soluble Rnq1 protein conformers into benign amyloid conformers, we 
hypothesize that this process can also result in the formation of toxic protein species. We 
refer to this as non-productive templating, which occurs when the cellular capacity to 
facilitate amyloid formation is exceeded or impeded (Figure 2).  
The notion of non-productive templating offers a unifying explanation for the 
observation that amyloid formation is sometimes associated with toxicity even when the 
amyloid form itself is benign. We discuss two cases in point: As mentioned earlier, the 
expression of GPI-anchorless PrP resulted in the formation of amyloid plaques but was 
not overtly toxic. However, when GPI-anchorless PrP was expressed together with WT 
PrP, deposits of both amyloid and non-amyloid PrPres formed and the clinical 
manifestations of scrapie disease were enhanced44. It has been suggested that PrPres 
subverts a stress protective function of PrP into an apoptotic signal59. The toxic signal 
elicited is dependent on the presence of PrPres and the expression of GPI-anchored PrP59. 
PrPres may influence the folding state of the GPI-anchored PrP through incomplete 
templating and thus cause the induction of a toxic signal.  
The second case in point involves the fungal prion [Het-s]. Non-productive 
templating can explain how the [Het-s] prion mediates heterokaryon incompatibility in 
the fungus Podospora anserina60. Heterokaryon incompatability, a type of programmed 
cell death, results when two cells with incompatible geneotypes, het-s and het-S, fuse to 
form a mixed cytoplasm. The two alleles encode distinct sequence variants of the Het-s 
protein. One, HET-s, is able to form the [Het-s] prion, where as the other, HET-S, cannot 
adopt an amyloid conformation. The prion form of the HET-s allele by itself is 
completely benign. However, if the HET-S allele is expressed in the presence of the [Het-
s] prion form it results in cell death. The interaction of HET-s protein with the [Het-s] 
prion form leads to the templated formation of additional non-toxic prion amyloid. On the 
other hand, we speculated that non-productive templating of the HET-S protein variant, 
which cannot form amyloid, by the [Het-s] prion form leads to the formation of a toxic 
misfolded species resulting in cell death (Figure 2).  
 
Conclusions 
The protein deposits that are the hallmark of neurodegenerative diseases are now 
seen in a different light. Formerly viewed as the cause of cellular dysfunction and 
neuronal loss, intracellular protein deposits, especially, are the product of a regulated 
cellular process enabling cells to cope with the accumulation of misfolded and damaged 
proteins. This notion is supported by studies demonstrating that the deposition of 
damaged and misfolded proteins in inclusions enables mitotic cells, ranging from the 
unicellular organism Escherichia coli to human embryonic stem cells, to asymmetrically 
segregate the accumulated damage to the daughter cell with the shorter life expectancy57, 
61-64. Based on our results in yeast, we suggest that inefficiencies in inclusion body and 
plaque formation, arising with accumulating protein damage, can result in the inception 
of toxic protein species due to non-productive templating. Further studies are needed to 
elucidate which types of protein deposits in the individual diseases are protective and 
how their formation circumvents the formation of more toxic species, such as prefibrillar 
oligomers.  
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Figure Legends 
Figure 1) Aggregation of misfolded protein can give rise to oligomers, amorphous 
aggregates and inclusion bodies. 
The accumulation of misfolded protein leads to the formation of different protein 
assemblies. Prefibrillar oligomers formed by different proteins share a common structure 
and are thought to be the toxic protein species in diseases such as Alzheimer’s and 
Huntington’s5, 6. Oligomers are conformationaly molten and can associate to form 
amorphous aggregates or convert to an amyloidogenic nucleus to initiate amyloid fibril 
formation. Amyloid fibrils have a highly organized structure due to repeating β-sheets 
and are insoluble. Amyloid fibrils are often found in intra- and extracellular inclusions 
such as inclusion bodies and amyloid plaques. The generation of amyloid fibers and 
inclusion bodies can protect cells by reducing the formation of highly interactive toxic 
oligomers and amorphous aggregates. 
 
Figure 2) Amyloid and Non-productive templating  
Amyloid fibrils grow by causing protein of the same amino-acid sequence to adopt the 
same amyloid conformation. This is referred to as amyloid templating and involves the 
efficient addition of monomer or oligomeric species to the amyloid fiber, which maybe 
assisted by specific chaperones (e.g. Rnq1 and the Hsp40 Sis1, Sup35NM and Hsp10449). 
If the amount of substrate exceeds the cellular capacity for amyloid conversion or if 
amino acid sequences are incompatible, the interaction with the amyloid fibrils may give 
rise to other abnormal conformational species, which may go on to form toxic oligomers 
and amorphous aggregates (Rnq1, PrP and Het-s/S). We refer to this as non-productive 
templating.  


